In a case series of 10 pregnant women with polycystic ovary syndrome and COVID‐19, recurrent miscarriages co‐occurred with plasminogen activator inhibitor elevation, MTHFR polymorphisms, and HHcy; personalized antithrombotic/immunomodulatory therapy yielded favorable outcomes (Jerzak and Szafarowska 2022). This evidence concerns the gene MTHFR and polycystic ovary syndrome.